Dendreon Corporation

Dendreon Corporation is a commercial-stage biopharmaceutical company based in Seal Beach, California. The company employs approximately 377 individuals and generates an annual revenue of $500 million. Dendreon specializes in the development and commercialization of immunotherapies. Their flagship product, PROVENGE (sipuleucel-T), is a groundbreaking immunotherapy made from a patient's own immune cells. This treatment has been FDA-approved for the treatment of advanced prostate cancer and has been prescribed to more than 40,000 men in the United States since 2010. Dendreon is also actively researching the potential of PROVENGE in treating early-stage prostate cancer with the aim of achieving a cure for more patients. Dendreon's commitment to immunotherapy sets them apart as a pioneer in the field. Their focus on developing personalized treatments using a patient's own immune system offers a unique and promising approach to cancer therapy. For more information about Dendreon Corporation and their innovative products, please visit their website at dendreon.com.